MoonLake Immunotherapeutics
NASDAQ:MLTX
Income Statement
Earnings Waterfall
MoonLake Immunotherapeutics
Income Statement
MoonLake Immunotherapeutics
| Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
5
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | ||||||||||||||||
| Operating Expenses |
(69)
|
(54)
|
(63)
|
(65)
|
(62)
|
(58)
|
(56)
|
(54)
|
(61)
|
(78)
|
(109)
|
(143)
|
(171)
|
(201)
|
(229)
|
|
| Selling, General & Administrative |
(23)
|
(27)
|
(27)
|
(23)
|
(23)
|
(21)
|
(21)
|
(22)
|
(24)
|
(26)
|
(28)
|
(30)
|
(35)
|
(39)
|
(42)
|
|
| Research & Development |
(46)
|
(27)
|
(36)
|
(42)
|
(39)
|
(37)
|
(35)
|
(32)
|
(37)
|
(52)
|
(81)
|
(113)
|
(136)
|
(162)
|
(187)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(69)
N/A
|
(54)
+22%
|
(63)
-16%
|
(65)
-4%
|
(62)
+5%
|
(58)
+7%
|
(56)
+3%
|
(54)
+3%
|
(61)
-13%
|
(78)
-28%
|
(109)
-38%
|
(143)
-32%
|
(171)
-19%
|
(201)
-18%
|
(229)
-14%
|
|
| Pre-Tax Income | ||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(2)
|
(5)
|
|
| Total Other Income |
0
|
0
|
0
|
1
|
1
|
2
|
3
|
10
|
15
|
20
|
26
|
22
|
23
|
24
|
21
|
|
| Pre-Tax Income |
(69)
N/A
|
(54)
+22%
|
(62)
-16%
|
(64)
-3%
|
(61)
+6%
|
(56)
+8%
|
(53)
+6%
|
(44)
+16%
|
(46)
-4%
|
(58)
-27%
|
(82)
-42%
|
(121)
-47%
|
(147)
-22%
|
(179)
-21%
|
(213)
-19%
|
|
| Net Income | ||||||||||||||||
| Tax Provision |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Income from Continuing Operations |
(69)
|
(54)
|
(62)
|
(65)
|
(61)
|
(56)
|
(53)
|
(44)
|
(46)
|
(58)
|
(83)
|
(121)
|
(148)
|
(179)
|
(214)
|
|
| Income to Minority Interest |
0
|
0
|
0
|
15
|
18
|
20
|
22
|
8
|
5
|
3
|
2
|
2
|
3
|
3
|
3
|
|
| Net Income (Common) |
(69)
N/A
|
(54)
+22%
|
(62)
-16%
|
(50)
+20%
|
(43)
+14%
|
(36)
+17%
|
(31)
+15%
|
(36)
-18%
|
(41)
-13%
|
(55)
-35%
|
(81)
-47%
|
(119)
-47%
|
(145)
-22%
|
(176)
-21%
|
(210)
-19%
|
|
| EPS (Diluted) |
-2.49
N/A
|
-1.53
+39%
|
-1.68
-10%
|
-1.7
-1%
|
-1.1
+35%
|
-0.81
+26%
|
-0.57
+30%
|
-0.73
-28%
|
-0.64
+12%
|
-0.87
-36%
|
-1.29
-48%
|
-1.89
-47%
|
-2.3
-22%
|
-2.79
-21%
|
-3.33
-19%
|
|